Axol Bioscience has signed an exclusive agreement with StrataStem to access and commercialise its collection of Alzheimer’s Disease (AD) patient samples. Harnessing its stem cell expertise, Axol will reprogramme these patient samples into induced Pluripotent Stem Cells (iPSCs) that can then be differentiated into a range of brain cells, including neurons and neuroinflammatory cells. […]
